Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Twinkle Twinkle Little Star
up above the board so high
Buhahahahahahah
they haven't slept!
They shit on themselves!
They tried the onslaught!
pathetic
maybe someone went a little too short!
it would be curious if tomorrow they launch a partnering
90 mil cash
MarzAA and DalcA have shown sustained efficacy and safety in mid-stage clinical trials and are available for partnering.
CB 2679d-GT has obtained preclinical proof-of-concept and is also available for partnering.
Want partnering
This sale is part of the ongoing strategic process that we announced in February to explore alternatives and create value for shareholders. We have significantly reduced our cash burn and continue to work with our advisors to evaluate additional strategic alternatives for Catalyst
I have the feeling that everyone who sells at 1 will buy at 2!
INTERESTING MC
Ms. Clancy commented, “I’m honored to be reprising the role of Chair at ObsEva at this pivotal time and building on the momentum created by Frank and the executive team as ObsEva prepares for commercial launch. My dedication to ObsEva and conviction in its prospects is long-standing, and I am excited to be presiding over this potentially transformational period as we pursue our first approvals and seek to change the treatment paradigm for women with uterine fibroids and other underserved conditions.”
Dr. Verwiel commented, “It is a privilege to have been part of the exceptional team at ObsEva over the past six years, and I take great pride in all that we have accomplished together. I look forward to following ObsEva’s continued achievement as the company nears prospective approval of linzagolix and pursues its vision of delivering life-changing therapies to address the most challenging unmet needs facing women.”
They almost almost buy some
Selective inhibition of the JAK2/STAT3 axis, an IFN-?, IL-6 and IL-23 receptor signaling response element, by Pacritinib (SB1518) was also shown to significantly reduce GVHD in murine models (181, 225). Similar to the effects of the JAK/STAT3 inhibitor Fedratinib in early MLR experiments; Pacritinib, led to impaired expansion of Th1 and Th17 cells while Treg and Th2 responses were sustained (181, 182). A recent study also reported a successful combinatory therapy of acute GVHD with Pacritinib the STAT3 inhibitor S31-201 and the mTOR inhibitor Rapamycin in a xenogeneic mouse model and with Rapamycin and the calcineurin inhibitor Tacrolismus in patients (166).
https://www.frontiersin.org/articles/10.3389/fimmu.2021.806529/full
Geneva, Switzerland and Boston, MA – April 7, 2022 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today published the invitation to its 2022 Annual General Meeting of Shareholders to be held on May 18, 2022 at 16:30 CEST at the company's offices in Geneva, Chemin des Aulx 12, 3rd floor, 1228 Plan-les-Ouates, Switzerland.
The agenda of the meeting will be as follows:
1 Approval of the Annual Report, the Statutory Financial Statements and theConsolidated Financial Statements for Fiscal Year 2021
The Board of Directors proposes that the annual report, the statutory financial statements and the consolidated financial statements of ObsEva SA for fiscal year 2021 be approved.
2 Discharge of Liability for the Members of the Board of Directors and of the Executive Committee
The Board of Directors proposes that shareholders release the members of the Board of Directors and of the Executive Committee from liability for their activities during fiscal year 2021.
3 Appropriation of Financial Results
The Board of Directors proposes that the loss of USD 55,480,053 for the financial year 2021 be appropriated as follows:
Financial Year 2021
Accumulated losses brought forward from previous year USD 328,451,570
Net loss for the year 2021 USD 55,480,053
Accumulated losses to be carried forward USD 383,931,623
4 Elections to the Board of Directors and Election of the Chairperson of the Board of Directors
Shorooooooooooooooooty!
Many kisses!
https://fintel.io/so/us/ctic
https://fintel.io/sst/us/ctic
ASC
Russell
SALES RESULT
BO
https://www.tipranks.com/news/blurbs/cti-biopharma-ctic-receives-a-buy-from-jmp-securities?utm_source=stck.pro&utm_medium=referral
they forgot zevalin and trisenox
https://www.biospace.com/article/releases/cti-biopharma-receives-10-million-milestone-payment-for-trisenox-/
https://investor.sppirx.com/news-releases/news-release-details/spectrum-pharmaceuticals-and-cell-therapeutics-jointly-market
having exceeded our internal projections with $2.5 million in net product sales in just a few weeks.
So no RS for now!
What's boiling in the pot?
Will investors be begging for an RS in order to stay listed on the NASDAQ?
Will they have found an institutional investor?
Who will be the CEO?
Meanwhile, a small nugget found: MDT's supply chain
https://www.globenewswire.com/news-release/2022/05/09/2438181/0/en/ObsEva-Presents-Clinical-Data-on-Oral-GnRH-Antagonist-Linzagolix-for-the-Treatment-of-Uterine-Fibroids-at-the-2022-ACOG-Annual-Clinical-and-Scientific-Meeting.html
We are encouraged by these additional analyses and post-treatment data from the PRIMROSE Phase 3 study that continue to underscore linzagolix's clinical utility and differentiated profile," said Dr. Brandi Howard, Chief Clinical Officer of ObsEva. "The results demonstrate that linzagolix has the potential to balance safety, efficacy, and address the wide-ranging symptoms of uterine fibroids. Linzagolix shows promise in delivering sustained clinical benefit, and if approved, would be the only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy to better address the individual needs of patients."
Ouch! Let's hope they won't punish her for the news
(”’)O__O(”’)
-\ '( o_o )' /-
–\ \_[ ]_/ /—Hands up!!!
—l . . . . l—
-—l . . . l—
–/ ./ – \. \–
-(,,,)__(,,,)-
Will it be as you say? MDT has bought all the companies where they have set their sights!
Elsewhere they paid dearly but here as you say they saved! We will see if they will be discouraged if we are the first to have taken it in that place!
For now it seems that the intertwining is deeper and deeper and this gives me hope!
Livendi will buy soon!
Because MDT
MDT is a good reason to cover!
We miss that they declare that they have bought the 5% ... I see it probable
It is cheap!
Oh this is good!
The order covers the purchase of instruments and cameras that will be used in preclinical activities and the evaluation of Titan Medical as a potential manufacturing and supply partner for Medtronic.
happy to know that we are in the MDT supply chain
COME ON !
Let us see the rock
Do you think it's time to sell?
mmmmm NAah
I hold
MC 500 mil
Hehehehehehehehehehe
so beauty!
According to the U.S. National Institutes of Health (NIH), 20-25% of women of reproductive age have fibroids.
https://www.health.ny.gov/community/adults/women/uterine_fibroids/
Yselty is indicated for treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.
Assuming 10/20% have moderate to severe symptoms of uterine fibroids ... the numbers are staggering!
it seems that patience is needed!
3.6. Initial applications in the decision-making phase
3.6.1. linzagolix choline - EMEA/H/C/005442
for the management of heavy menstrual bleeding (HMB) associated with uterine fibroids Scope: Revised opinion
Action: For adoption
List of Questions adopted on 24.02.2022. Opinion adopted on 16.12.2021. List of Outstanding Issues adopted on 11.11.2021, 16.09.2021. List of Questions adopted on 22.04.2021.
https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-19-22-april-2022-meeting_en.pdf#page16
it's almost time!
a nice handle thanks /
The Company’s consolidated financial statements as of December 31, 2021 were prepared under the assumption that the Company will continue as a going concern. At December 31, 2021, the Company had cash and cash equivalents of $19.0 million. Given the Company’s current plans, the Company estimates cash resources will be sufficient to fund its operations through the second quarter of 2023.
MC 7,5
Mmmmm
I hold
https://sedar.com/CheckCode.do
8 jun
26 april for record
this will also be virtual
https://d1io3yog0oux5.cloudfront.net/_a678a012471396afb6a663ae1a93c436/titanmedicalinc/db/1153/9835/pdf/Titan+Medical+2021+AGM+Virtual+User+Guide.pdf
but who sells it for 5?
a wanker